The clinical significance of p21WAF1/CIP-1 and p53 expression in pancreatic adenocarcinoma

Cancer

Volumn 80, Issue 3, 1997, Pages 372-381

  Dergham, Sanaa T ^a   Dugan, Michael C ^a   Joshi, Urwashi S ^a   Chen, Yong C ^a   Du, Wei ^a   Smith, Daryn W ^a   Arlauskas, Patricia ^a   Crissman, John D ^a   Vaitkevicius, Vainutis K ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; p21; p53; Pancreatic adenocarcinoma; Radiation therapy; Survival; Tumor suppressor genes; WAF1

Indexed keywords

PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER STAGING; DISEASE ASSOCIATION; GENE ACTIVATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL RATE;

ADENOCARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030814597     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970801)80:3<372::AID-CNCR4>3.0.CO;2-U     Document Type: Article

References (37)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;65:5-27.
2. Whipple AO, Parsons WB, Mullins CR. Treatment of cancer of the ampulla of vater. Ann Surg 1935;102:763-79.
3. Weinberg RA. Tumor suppressor gene. Science 1991; 254:1138-46.
4. Levine LA, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
5. Marshall CJ. Tumor suppressor genes. Cell 1991;64:313-26.
6. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
7. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. p53 mutations in human cancer. Science 1991;253:49-53.
8. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
9. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;142:1534-43.
10. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:151-60.
11. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solicia E, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994;54:1556-60.
12. Suzuki T, Takano Y. Comparative immunohistochemical studies of p53 and proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions in pancreatic duct cell carcinomas. Jpn J Cancer Res 1993;84:1072-7.
13. Zhang SY, Ruggeri B, Agarwal P, Sorling AF, Obara T, Ura H, et al. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994;118:150-4.
14. DiGiuseppe JA, Hruban RH, Goodman SN, Polak M, van den Berg FM, Allison DC, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994;101:684-8.
15. Nakamori S, Yashima K, Murakami Y, Ishikawa O, Ohigashi H, Imaoka S, et al. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 1995;86:174-81.
16. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33.
17. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78.
18. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
19. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
20. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
21. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
22. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994;211:90-8.
23. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM. Interaction of the p53-regulated protein GADD45 with proliferating cell nuclear antigen. Science 1994;266:1376-80.
24. Lowe SW, Jacks T, Housman DE, Ruley HE. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci U S A 1994;91:2026-30.
25. Lowe SW, Bodis S, McClatchey A, Reminton L, Ruley HE, Fisher DE, et al. P53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
26. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53 independent pathway. Cancer Res 1994;54:3391-95.
27. DiGiuseppe JA, Hruban RH. Pathobiology of cancer of the pancreas. Semin Surg Oncol 1995;11:87-96.
28. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994;9:3389-96.
29. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CiP1 expression in the absence of p53. Oncogene 1994;9:3397-406.
30. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267:1018-24.
31. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, et al. P53-independent expression of p21 Cip1 in muscle and other terminally differentiating cells. Science 1995; 267:1024-7.
32. p21WAF1/Cip1 expression in normal and neoplastic tissues. Cancer Res 1995; 55:2910-9.
33. Zhang H, Hannon GJ, Casso D, Beach D. p21 is a component of active cell cycle kinases. Cold spring harbor symposia on quantitative biology, 1994, Vol. LIX 21-29. New York: Cold Spring Laboratory Press, 1994.
34. Schiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994;84:3781-4.
35. Chen YQ, Cipriano SC, Sarkar FH, Ware JL, Arenkiel JM. P53-independent induction of p21(WAF1) pathway is preserved during tumor progression. Int J Oncol 1995;7:889-93.
36. Joshi US, Chen YQ, Miller FR, Dergham ST, Dugan MC, Crissman JD, Vaitkevicius VK, Sarkar FH. Inhibition of pancreatic tumor cell growth in culture by p21WAF-1 (p21)-recombinant adenovirus. Annual Meeting of the American Pancreatic Association, Chicago, IL. Pancreas 1996;13:442.
37. Chen YQ, Cipriano SC, Arenkiel JM, Miller FR. Tumor suppression by p21WAF1. Cancer Res 1995;55:4536-9.